CJC-1295 Chronic Tendinopathy Protocol: Dosing, Timing, and Evidence

Why Chronic Tendinopathy Is Hard to Treat

Chronic tendinopathy is not simply persistent inflammation. Histologically, the tissue shifts to a degenerative phenotype called tendinosis, characterized by disorganized collagen type I, increased type III collagen deposition, neovascularization, and a near-absence of inflammatory cells. This is a repair failure, not a sustained inflammatory cascade.

Standard care has a ceiling. A 2015 Cochrane review of exercise therapy for patellar tendinopathy (28 trials, N=1,800+) found that eccentric loading programs produced meaningful pain reduction in roughly 60% of patients, leaving a substantial minority with persistent dysfunction [1]. Platelet-rich plasma (PRP) showed inconsistent results across three high-quality RCTs reviewed in that same body of literature.

The Repair-Biology Gap

Tendons are hypovascular and hypocellular. Tenocytes turn over slowly, and their anabolic capacity declines with age and mechanical overload. The growth hormone/IGF-1 axis is one of the few endogenous pathways with direct evidence of stimulating tenocyte proliferation and collagen I synthesis. Serum IGF-1 correlates positively with tendon cross-sectional area in healthy adults, as demonstrated in a 2007 cross-sectional study in the Journal of Applied Physiology (N=80) [2].

Where CJC-1295 Fits

CJC-1295 does not deliver exogenous GH. It extends the half-life of endogenous GHRH from roughly 7 minutes to 6 to 8 days (DAC isoform), producing sustained GH pulsatility rather than a supraphysiologic spike. This pharmacokinetic profile is mechanistically favorable for tissue remodeling because pulsatile, physiologic-range GH secretion drives IGF-1 production in the liver and locally within tendon fibroblasts without the receptor downregulation seen with continuous GH infusion.

Mechanism of Action: CJC-1295 and the GH/IGF-1 Axis in Tendon

CJC-1295 binds and activates the GHRH receptor on pituitary somatotrophs, increasing both GH pulse amplitude and frequency. The DAC (Drug Affinity Complex) modification covalently attaches the peptide to circulating albumin, extending its effective window and allowing twice-weekly or three-times-weekly dosing.

GH and Collagen Synthesis

Exogenous GH increases type I procollagen synthesis markers in multiple human trials. A randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) showed that GH administration over 12 weeks increased serum PINP (a collagen synthesis marker) by approximately 40% above baseline in GH-deficient adults [3]. Tendons express both GH receptors and IGF-1 receptors locally, meaning the effect is not purely systemic.

IGF-1 and Tenocyte Biology

IGF-1 stimulates tenocyte proliferation and upregulates collagen I gene expression in vitro. In an animal model of Achilles tendon injury, local IGF-1 delivery accelerated histologic tendon healing at 4 weeks compared with saline controls (P<0.01) [4]. CJC-1295 does not deliver IGF-1 directly; it elevates the upstream signal that the liver and local tissues use to produce IGF-1.

Animal Model Evidence for GHRH-Axis Peptides in Tendon

A rodent study using a synthetic GHRH analogue (MR-409, structurally related to CJC-1295) demonstrated improved load-to-failure mechanics in an Achilles transection model at 6 weeks post-intervention, along with higher collagen fiber alignment scores on picrosirius red staining [5]. This is preclinical data. Extrapolation to human tendinopathy requires caution, but the mechanistic pathway is biologically coherent.

The CJC-1295 Chronic Tendinopathy Protocol

There is no FDA-approved protocol for this indication. The following structure draws on published GH-axis pharmacokinetics, the preclinical tendon literature, and structured practitioner frameworks used in sports-medicine and longevity settings. Each component below is labeled by evidence level.

Isoform Selection: DAC vs. No-DAC

CJC-1295 with DAC is the standard choice for tendinopathy protocols because the extended half-life (6 to 8 days) allows twice-weekly dosing and produces a sustained IGF-1 elevation rather than a brief spike. A 2006 pharmacokinetic study in the Journal of Clinical Endocrinology and Metabolism confirmed that a single 30 mcg/kg dose of CJC-1295 with DAC elevated mean GH concentrations 2- to 10-fold above baseline for up to 6 days and raised IGF-1 levels by 20 to 30% above baseline sustained over 14 days [6]. Evidence level: human PK study (non-tendon endpoint).

CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of approximately 30 minutes and must be dosed daily or twice daily. It produces a sharper, more physiologic GH pulse and may be preferred in patients who need tighter GH titration or have borderline fasting glucose.

Dosing

| Parameter | CJC-1295 with DAC | CJC-1295 without DAC | |---|---|---| | Dose per injection | 300 to 500 mcg | 100 to 200 mcg | | Frequency | 2 to 3 times/week | Daily (5 days on, 2 off) | | Route | Subcutaneous | Subcutaneous | | Timing | Any time; avoid within 30 min of a meal | Before sleep or post-workout | | Cycle length | 12 to 16 weeks | 12 to 16 weeks | | Rest period | 4 to 8 weeks off before repeating | 4 to 8 weeks off |

Dosing at the lower end of the range (300 mcg with DAC) is appropriate for patients who are older than 50, have baseline IGF-1 above 200 ng/mL, or have any metabolic risk factors.

Injection Technique

Subcutaneous injection into the abdomen or lateral thigh is standard. Rotate sites each injection to avoid lipohypertrophy. Reconstitute lyophilized CJC-1295 with bacteriostatic water (1 to 2 mL per 2 mg vial). Use 29- or 31-gauge insulin syringes. Store reconstituted peptide at 2 to 8°C and use within 28 days.

Combination Strategies

In practitioner experience, CJC-1295 is rarely used as a monotherapy for tendinopathy. Two combinations appear most commonly in clinical case series and structured practitioner reports:

CJC-1295 + Ipamorelin. Ipamorelin is a selective ghrelin-receptor agonist (GHSR agonist) that augments GH pulse amplitude without significantly raising cortisol or prolactin. Combining it with CJC-1295 targets two different steps in GH release simultaneously. A typical combination dose is CJC-1295 300 mcg + Ipamorelin 200 mcg injected together, three times per week, before bed. Evidence level: pharmacodynamic rationale; no tendon-specific RCT.

CJC-1295 + BPC-157. BPC-157 is a 15-amino acid peptide derived from body protection compound in gastric juice. Rodent studies have shown BPC-157 accelerates tendon-to-bone healing and promotes angiogenesis in chronic tendon injury models, with one study reporting significantly faster Achilles tendon transection repair (P<0.05 vs. Controls at 4 weeks) [7]. The mechanistic rationale for combining BPC-157 (local tendon repair signaling) with CJC-1295 (systemic GH/IGF-1 elevation) is logically additive, though no human RCT has tested this combination in tendinopathy.

Expected Clinical Timeline

Tendon remodeling is slow. Setting accurate patient expectations is as important as selecting the right dose.

Weeks 1 to 4: Symptom Modulation

Many patients report subjective improvement in sleep quality, recovery from training sessions, and mild pain reduction within the first 2 to 4 weeks. These effects may relate to GH-mediated improvements in soft-tissue recovery rather than meaningful structural tendon change. Structural change at 4 weeks is unlikely.

Weeks 4 to 8: Early Tissue Response

If IGF-1 is rising appropriately (target: upper third of age-adjusted normal range, typically 200 to 280 ng/mL in adults under 50), early increases in tenocyte metabolic activity are biologically plausible based on in vitro data. Clinically, patients typically notice reduced morning stiffness and improved tolerance of loading exercises.

Weeks 8 to 16: Structural Remodeling Window

Tendon collagen remodeling requires a minimum of 8 to 12 weeks to produce measurable structural change by ultrasound or MRI. Patients continuing structured eccentric loading programs alongside CJC-1295 are most likely to see meaningful improvements in tendon thickness normalization and fiber organization. A 2018 study in the British Journal of Sports Medicine found that tendon structural changes on ultrasound tissue characterization lagged symptom improvement by 6 to 12 weeks in patients undergoing conservative management of Achilles tendinopathy (N=46) [8]. Evidence level: observational cohort.

Monitoring: Labs and Clinical Endpoints

Baseline Labs (Before Starting)

• IGF-1 (serum): establishes starting point; guides dose selection
• Fasting glucose and HbA1c: GH is diabetogenic at supraphysiologic levels; screen before starting
• Fasting insulin: identifies insulin resistance at baseline
• CBC with differential: general safety screen
• Comprehensive metabolic panel: hepatic and renal function
• PSA (men over 40): precaution given IGF-1's mitogenic potential in prostate tissue

Week 8 Recheck

• IGF-1: target the upper third of age-adjusted normal range. An IGF-1 above 350 ng/mL warrants dose reduction or temporary discontinuation.
• Fasting glucose and HbA1c: if fasting glucose exceeds 100 mg/dL from a normal baseline, reduce dose or switch to the no-DAC isoform with lower per-dose GH stimulus.
• Clinical tendon assessment: Victorian Institute of Sport Assessment (VISA) score for Achilles (VISA-A) or patellar (VISA-P) tendinopathy; record at baseline, week 8, and end of cycle.

Contraindications and Cautions

• Active malignancy or personal history of hormone-sensitive cancer: IGF-1 elevation is contraindicated.
• Proliferative diabetic retinopathy: GH elevation may worsen retinal status.
• Acromegaly or pituitary adenoma: any GHRH analogue is contraindicated.
• Pregnancy: no safety data; avoid.
• Pediatric patients: open epiphyses; use only under specialist supervision.

Loading Program: Peptide Therapy Does Not Replace Rehabilitation

CJC-1295 is a biological signal, not a structural repair. Without mechanical loading, tendons do not remodel effectively even in a GH-replete state. The most evidence-supported rehabilitation program for recalcitrant tendinopathy remains heavy slow resistance (HSR) training.

A 2015 randomized trial in the British Journal of Sports Medicine (N=58 with chronic patellar tendinopathy) found HSR training produced equivalent 12-month outcomes to eccentric training, with superior patient satisfaction scores (P<0.05) [9]. The Alfredson eccentric protocol (heel drop for Achilles, decline squats for patellar) remains the reference comparator in clinical trials.

Patients on CJC-1295 protocols should maintain their structured loading program 3 to 5 times per week throughout the 12 to 16 week cycle. The peptide-plus-loading model is the only evidence-adjacent framework available; peptide alone, without mechanical stimulus, is unsupported even by the animal literature.

Evidence Quality Summary

The table below maps each protocol element to its highest available evidence level, giving clinicians and patients a transparent picture of where the science is solid and where it relies on inference.

| Protocol Element | Best Evidence Level | Source Type | |---|---|---| | CJC-1295 raises IGF-1 in humans | Level 2 | Human PK/PD study [6] | | GH/IGF-1 increases collagen synthesis | Level 2 | Human crossover RCT [3] | | GHRH analogue improves tendon mechanics | Level 4 | Rodent model [5] | | BPC-157 accelerates tendon healing | Level 4 | Rodent model [7] | | Eccentric/HSR loading for tendinopathy | Level 1 | Multiple RCTs [1,9] | | CJC-1295 specifically treats tendinopathy | Level 5 | No human data; inference only |

Clinicians should discuss this evidence field explicitly with patients before initiating treatment. The absence of a human tendinopathy RCT means the protocol rests on mechanistic inference supported by adjacent human GH data and preclinical models.

Regulatory and Compounding Considerations

CJC-1295 is not FDA-approved for any indication. In the United States, it may be legally compounded for individual patients under section 503A of the Federal Food, Drug, and Cosmetic Act by a licensed compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [10]. Bulk peptide sourced outside this pathway (research-chemical vendors) carries unknown purity, sterility, and concentration accuracy, and its use is outside the scope of legitimate clinical practice.

The FDA has issued guidance restricting certain peptides from 503A compounding; practitioners should verify current compounding status at the time of prescribing, as the regulatory field changes. As of the date of this article, CJC-1295 remains available through licensed 503A compounders in most U.S. States.

Special Populations

Older Adults (Age 50+)

GH secretion declines approximately 14% per decade after age 30, so older patients with chronic tendinopathy may have the most to gain from GHRH augmentation. Start at 300 mcg with DAC, twice weekly. Monitor IGF-1 at 6 weeks rather than 8 weeks given slower metabolic clearance.

Female Patients

Women have higher baseline GH pulse frequency but lower pulse amplitude than men. The same dosing range applies, but women tend to reach target IGF-1 levels at the lower end of the dose range. Estrogen status affects IGF-1 sensitivity; postmenopausal women not on hormone therapy may need slightly higher doses to achieve equivalent IGF-1 response.

Athletes Subject to Testing

CJC-1295 falls under the World Anti-Doping Agency (WADA) prohibited list as a GHRH analogue (class S2: peptide hormones, growth factors, and related substances) [11]. Competitive athletes subject to testing should not use this protocol.

Physician Perspective on Patient Selection

The patients most likely to benefit from a CJC-1295 tendinopathy protocol share several characteristics: tendinopathy confirmed by ultrasound or MRI showing tendinosis rather than acute tear, failure of at least 12 weeks of structured HSR or eccentric loading, age-adjusted IGF-1 in the lower half of normal range at baseline, and no metabolic contraindications. Patients with normal or elevated baseline IGF-1 have a weaker biological rationale for GHRH augmentation, and the risk-benefit ratio shifts unfavorably.

"The GH/IGF-1 axis is one of the few endogenous anabolic pathways with mechanistic support for collagen synthesis. Patients who have genuinely exhausted standard rehabilitation deserve a structured conversation about the current state of the evidence, including its limitations," notes the HealthRX Medical Advisory Board in their 2024 internal peptide-therapy guidance document.